Septodont’s Novocol Pharma division has secured $32.7 million Canadian ($26 million U.S.) from the Canadian government to further develop its injectable products.
The funding will increase biomanufacturing capability of fill-finish sterile injectables at Novocol Pharma’s facility in Cambridge, Ontario, Septodont said.
